Clinical Trial Update: Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 [Phase 1]

View source ↗

Summary

Phase 1 trial in head and neck cancer evaluating secondary primary tumor prevention using an EGFR inhibitor (gefitinib/OSI-774) in combination with a COX-2 inhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: Emory University | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED